间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展

doi:10.6040/j.issn.1671-7554.0.2020.224

摘要/Abstract

摘要： 当前新型冠状病毒肆虐,严重危害人类健康、社会经济发展及全球医疗和公共卫生系统。新型冠状病毒传染性强,潜伏期长,疫情控制难度大,引起重症、危重症及死亡病例众多,尚缺乏有效特异性治疗。过度的免疫反应引起的细胞因子风暴是新型冠状病毒感染导致急性呼吸窘迫综合征、脓毒症休克和多器官衰竭甚至死亡的关键因素。间充质干细胞具有强大的抗炎及免疫调节功能,可抑制细胞因子风暴的发生、发展,同时亦有强大的组织损伤修复的能力,双管齐下可发挥减轻肺损伤、降低急性呼吸窘迫综合征等严重并发症发生风险,有望降低患者的死亡率。目前已启动了多项间充质干细胞治疗新型冠状病毒肺炎的相关临床研究项目,初步证实了安全性及有效性,提示具有良好临床应用前景。

关键词: 新型冠状病毒肺炎, 间充质干细胞, 免疫调节, 损伤修复, 细胞因子风暴综合征

Abstract: The current spread of 2019 novel coronavirus pneumonia(2019-nCoV)seriously endangers human health, socio-economic development, as well as the global medical and public health system. The 2019-nCoV is highly contagious and lethal, characterized by long incubation period and difficulty control. More importantly, there is no specific and effective treatment for this disease so far. The cytokine storm caused by excessive immune response is a key factor leading to acute respiratory distress syndrome, septic shock, multiple organ failure, and even death. As mesenchymal stem cells(MSCs)have powerful anti-inflammatory and immunoregulatory potentials, which can inhibit the occurrence and development of cytokine storms and repair tissue damage, MSCs are expected to reduce lung injury, severe complications and mortality. The academic institutes in China have initiated several clinical research projects on MSCs for the treatment of 2019-nCoV, and have preliminarily confirmed its safety, effectiveness and clinical prospect.

Key words: Novel coronavirus pneumonia, Mesenchymal stem cells, Immune regulation, Damage repair, Cytokine storm syndrome

中图分类号:

R563.1

鞠秀丽. 间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展[J]. 山东大学学报 (医学版), 2020, 58(3): 32-37.

JU Xiuli. Potential mechanism and research progress of mesenchymal stem cells in the treatment of 2019 novel coronavirus pneumonia[J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 32-37.

参考文献 34

[1]	国家卫生健康委办公厅.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-19].http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.
[2]	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019 [J]. N Engl J Med, 2020, 382(8): 727-733.
[3]	Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. Lancet, 2020, 395(10223):470-473.
[4]	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223):507-513.
[5]	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
[6]	Daniel Wrapp, Nianshuang Wang, Kizzmekia S, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation[EB/OL].(2020-02-11)[2020-02-19]. doi: 10.1101/2020.02.11.944462.
[7]	张艳丽, 蒋澄宇. 细胞因子风暴:急性呼吸窘迫综合征中的主宰生命之手[J]. 生命科学, 2015, 27(5):554-557. ZHANG Yanli, JIANG Chengyu. Cytokine storm in ARDS[J]. Chinese Bulletin of Life Sciences, 2015, 27(5):554-557.
[8]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223):497-506.
[9]	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol, 2012, 86(11): 6055-6066.
[10]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Respir Med, 2020. doi: 10.1016/S2213-2600(20)30076-X.
[11]	Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8(9):726-736.
[12]	Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways[J]. Ann N Y Acad Sci, 2015, 1351: 114-126. doi: 10.1111/nyas.12815.
[13]	Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8):784.
[14]	Qin ZH, Xu JF, Qu JM, et al. Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism [J]. J Cell Mol Med, 2012, 16(11):2745-2753.
[15]	Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilatorinduced lung injury in the rat[J]. Thorax, 2012, 67(6):496-501.
[16]	Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema[J]. Respir Res, 2014, 15: 118. doi: 10.1186/s12931-014-0118-x.
[17]	Antebi B, Mohammadipoor A, Batchinsky AI, et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome [J]. J Trauma Acute Care Surg, 2018, 84(1): 183-191.
[18]	Wu X, Dao Thi VL, Huang Y, et al. Intrinsic immunity shapes viral resistance of stem cells[J]. Cell, 2018, 172(3):423-438.
[19]	Sobacchi C, Palagano E, Villa A, et al. Soluble factors on stage to direct mesenchymal stem cells fate[J]. Front Bioeng Biotechnol, 2017, 5(32): 1-9.
[20]	Ethokic JM, Tomic SZ, Colic MJ. Cross-talk between mesenchymal stem/stromal cells and dendritic cells [J]. Curr Stem Cell Res Ther, 2016, 11(1): 51-65.
[21]	Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells[J]. Cell Death Differ, 2018, 25(7):1209-1223.
[22]	Song Y, Dou H, Li X, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of IL-1β-primed mesenchymal stem cells against sepsis: IL-1β enhances immunomodulatory effect of MSCs[J]. Stem Cells, 2017, 35(5): 1208-1221.
[23]	Li S, Wu H, Han D, et al. A novel mechanism of mesenchymal stromal cell-mediated protection against sepsis: restricting inflammasome activation in macrophages by increasing mitophagy and decreasing mitochondrial ROS[J]. Oxid Med Cell Longev, 2018, 4(13): 3537609-3537623.
[24]	Fayyad-Kazan H, Faour WH, Badran B, et al. The immunomodulatory properties of human bone marrowderived mesenchymal stromal cells are defined according to multiple immunobiological criteria [J]. Inflamm Res, 2016, 65(6): 501-510.
[25]	Zanotti L, Angioni R, Cali B, et al. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1[J]. Leukemia, 2016, 30(5): 1143-1154.
[26]	Li B, Zhang H, Zeng M, et al. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharideinduced apoptosis partially by inhibiting the Wnt/β-catenin pathway[J]. Cell Biology International, 2015, 39(2): 192-200.
[27]	Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung [J]. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
[28]	Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. Coli endotoxin-induced acute lung injury in the ex vivo perfused human lung [J]. Proc Natl Acad Sci USA, 2009, 106(38): 16357-16362.
[29]	Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo[J]. Mediators Inflamm, 2016, 2016:2347938.doi: 10.1155/2016/2347938.
[30]	LI QC, LIANG Y, SU ZB. Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316(6):1107-1117.
[31]	Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1)virusassociated acute lung injury [J]. J Infect Dis, 2019, 219(2):186-196.
[32]	Zhang X, Gao F, Li Q, et al. MSCs with ACE II gene affect apoptosis pathway of acute lung injury induced by bleomycin[J]. Exp Lung Res, 2015, 41(1):32-43.
[33]	Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem(stromal)cells for treatment of ARDS: a phase 1 clinical trial [J]. Lancet Respir Med, 2015, 3(1): 24-32.
[34]	Ahn SY, Chang YS, Kim JH, et al. Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia [J]. J Pediatr, 2017, 185(1):49-54.

相关文章 15

[1]	曹义海. 血管生成在疾病治疗中的应用与展望[J]. 山东大学学报 (医学版), 2021, 59(9): 9-14.
[2]	杨璇,李岩志,马伟,贾崇奇. 基于两样本孟德尔随机化的肺功能与新型冠状病毒肺炎病死风险的因果关系[J]. 山东大学学报 (医学版), 2021, 59(7): 104-111.
[3]	周溪,黄霂晗,任玉洁,邱洋. 新型冠状病毒感染与天然免疫及炎症反应[J]. 山东大学学报 (医学版), 2021, 59(5): 15-21.
[4]	于莹,张功,刘晶,颜世童,韩涛,黄海量. 基于网络药理学和分子对接方法探析黄芪预防新型冠状病毒肺炎的潜在作用机制[J]. 山东大学学报 (医学版), 2021, 59(4): 6-16.
[5]	任敏敏,王广梅,张丽,杨瑶瑶,封丹珺. 335名抗疫一线护理人员心理弹性对共情疲劳的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 88-94.
[6]	山东大学齐鲁医院新型冠状病毒肺炎诊治专家组. 新型冠状病毒肺炎疑似病例诊断及管理专家共识·齐鲁医院标准[J]. 山东大学学报 (医学版), 2020, 58(3): 1-7.
[7]	山东大学齐鲁医院新型冠状病毒肺炎防控工作组. 山东大学齐鲁医院新型冠状病毒肺炎防控策略与实践[J]. 山东大学学报 (医学版), 2020, 58(3): 8-18.
[8]	李士雪,单莹. 新型冠状病毒肺炎研究进展述评[J]. 山东大学学报 (医学版), 2020, 58(3): 19-25.
[9]	周生余,王春亭,张伟,王锡明,董亮. 山东省新型冠状病毒肺炎患者537例临床特征与救治效果[J]. 山东大学学报 (医学版), 2020, 58(3): 44-51.
[10]	崔亮亮,耿兴义,赵小冬,杨国樑,常彩云,赵梦娇,李战,王春荣,刘岚铮,阮师漫. 济南市现阶段新型冠状病毒肺炎的流行特征与思考[J]. 山东大学学报 (医学版), 2020, 58(3): 52-57.
[11]	张孝国,马艳,肖嘉安,张忠法. 济南市儿童新型冠状病毒肺炎的临床特征[J]. 山东大学学报 (医学版), 2020, 58(3): 62-64.
[12]	徐焱焱,颜贝,王锐,王红燕. 经血间充质干细胞通过IGF-1信号通路改善小鼠卵巢早衰[J]. 山东大学学报 (医学版), 2020, 58(2): 13-20.
[13]	余雪源,张硕,燕芳芳,苏德振. 采用清肺排毒汤联合西药43例与单用西药46例的新型冠状病毒肺炎临床疗效比较[J]. 山东大学学报 (医学版), 2020, 58(12): 47-53.
[14]	牛占丛,王彦霞,王晓亚,王晓庆,李亚轻,边竞. 新型冠状病毒肺炎2例报告[J]. 山东大学学报 (医学版), 2020, 58(10): 134-136.
[15]	李秀君,李新楼,刘昆,赵晓波,马盟,孙博. 地理信息系统在新型冠状病毒肺炎疫情防控中的应用进展述评[J]. 山东大学学报 (医学版), 2020, 58(10): 13-19.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed